Metastatic breast cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HER2 193
• CDK4/6 49
• PIK3CA 24
• ESR1 11
• PD-L1 10
• BRCA1 2
• PI3K 13
• BRCA2 2
• PARP 7
• AKT 4
• PD-1 10
• STAT3 0
• PTEN 2
• TP53 0
• mTOR 5
• TROP2 4
• STING 0
• VEGF 4
• YAP 0
• PALB2 3
• MMP-9 0
• AR 0
• CXCR4 1
• EGFR 3
• HER3 4
• AMPK 0
• HDAC 1
• JAK 1
• CTNNB1 0
• FGFR 1
• PSMA 0
• ATM 0
• CD40 1
• EZH2 0
• FAK 0
• HIF-1 0
• MUC1 3
• PPAR 0
• BCL-2 1
• CD47 1
• COX-2 0
• ERK 0
• HSP90 0
• IGF1R 0
• IL-6 0
• MDM2 2
• MET 0
• MYC 0
• TNF 0
• B7-H3 1
• CCR5 0
• CSF1R 0
• CTLA-4 1
• JNK 0
• LAG-3 0
• MAPK 0
• NF1 0
• NRF2 0
• RANKL 0
• TIGIT 0

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, United States· until Oct 2028

• NIH NIDA · UG3

  Development of a Novel Treatment for Benzodiazepine Addiction

  University of Mississippi Med Ctr· Jackson, United States· US$1,753,289 awarded in fiscal year 2026· until Aug 2028

• NIH NINR · F31

  Clarifying symptom experiences and management strategies for breast cancer survivors with cardiotoxicity: A mixed-methods analysis

  University of South Florida· Tampa, United States· US$40,326 awarded in fiscal year 2026· until Jul 2028

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, United States· US$768,308 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R15

  Mechanotransduction from the tumor microenvironment to the nuclear envelope protein emerin enables nuclear softening during cancer metastasis

  Rowan University· Glassboro, United States· US$564,078 awarded in fiscal year 2026· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

  Cardiff University· Cardiff, United Kingdom· EU contribution €260,348· until Apr 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €252,180· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Re-wiring tumor immune-evasive plasticity with mRNA therapy (PLASTWIRE)

  Fundacio Institut Hospital del Mar D Investigacions Mediques· Barcelona, Spain· EU contribution €2,533,207· until Nov 2031

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multispecific theranostic nano-engager platform (Nano-BITE)

  Institut Gustave Roussy· Villejuif, France· EU contribution €150,000· until May 2028

  The disease is named only in the funder's project summary, not in the title.

10 of 2,366 running projects, newest first. Listed amounts together: US$1.3bn + €289.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

  NCT04756765· Stanford University· Updated 17 Aug 2025

  “Due to changes in the treatment landscape, the study faced significant recruitment challenges. As no patients were enrolled, the sponsor requested study closure”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 21
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 63
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 70
• Liquid Biopsy 19
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 64
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 58
• Genome-Wide Association Study 1

See which targets of this disease your abstract mentions, and go to the people working on them.